Mammalian Transient Protein Expression Market

Mammalian Transient Protein Expression Market Size, Market Forecast and Outlook By FMI

The mammalian transient protein expression market was valued at USD 804.3 million in 2025. The industry is expected to reach USD 848.5 million in 2026, and cross USD 1,449.4 million by 2036 at a 5.5% CAGR during the forecast period. Expression vectors are projected to account for 28.5% share in 2026, as plasmid design quality influences protein yield and screening speed. Bio-production is estimated to hold 40.0% share in 2026.

Summary of the Mammalian Transient Protein Expression Market

• Demand and Expansion Drivers
  • Antibody discovery supports platform use as screening teams need gram-scale protein samples before stable line selection.
  • Recombinant protein studies support repeat reagent purchases with vectors and transfection systems needed in every new construct cycle.
  • Contract research demand supports service expansion as small biotech firms outsource protein production before asset validation.
  • South Korea’s 6.4% CAGR reflects public and private biologics capacity across Seoul and Incheon clusters.
• Product and Segment View
  • Expression vectors are projected to lead with 28.5% share in 2026 as construct quality affects downstream assay reliability.
  • Bio-production is expected to hold 40.0% share with antibody and antigen supply supporting early drug work.
  • HEK293 is projected to account for 46.0% share in 2026 as fast expression suits difficult proteins and rapid screening.
  • Biopharma Companies are expected to lead end user with 48.0% share as internal teams run repeated candidate selection cycles.
  • Small Scale is projected to lead Scale with 42.0% share as most projects need milligram to gram quantities.
• Geography and Competitive Outlook
  • The USA is projected to record 5.8% CAGR through 2036 as research funding and biotech density support repeat purchases.
  • Germany is expected to expand at 5.6% CAGR through 2036 as biologics and process science programs support steady demand.
  • Thermo Fisher Scientific is estimated to dominate through its Expi systems and reagent breadth.
  • Merck KGaA and Cytiva compete through cell culture depth and service access. Sartorius and Lonza support demand through bioprocess platforms.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Consultant at FMI says, “Our team view mammalian transient protein expression less as a commodity reagent market and more as a strategic acceleration layer within biologics research. The value lies in how effectively platforms compress candidate screening timelines without introducing variability in cost or assay confidence. Rising antibody complexity and tighter protein quality expectations are fundamentally changing early discovery workflows. Teams are now required to evaluate a broader construct set before committing to stable cell‑line development.”
• Mammalian Transient Protein Expression Market Value Analysis
  • Revenue is projected to increase from USD 848.5 million in 2026 to USD 1,449.4 million by 2036.
  • Expression vectors lead product demand as construct design influences yield and protein quality before purification begins.
  • Bio-production forms the largest application base with antibody screening and recombinant antigen work supporting repeat usage.
  • Direct sales dominate as biopharma teams need technical support during construct and scale changes.
  • Price pressure is highest in academic labs as reagent costs build quickly across repeated transfection runs.

Key Takeaways

Metric	Value
Market Size (2025)	USD 804.3 Million
Market Size (2036)	USD 1,449.4 Million
CAGR (2026–2036)	5.5%
Incremental Opportunity (2026–2036)	USD 600.9 Million
Leading Product Type (2026)	Expression Vectors
Expression Vectors Share (2026)	28.5%
Leading Product Type (2026)	Bio-Production
Bio-Production Share (2026)	40.0%
Fastest-Growing Country	South Korea
South Korea CAGR	6.4%

Mammalian Transient Protein Expression Market Definition

The mammalian transient protein expression market covers systems used to produce recombinant proteins without stable genome integration. Scope includes plasmid vectors and transfection reagents. It includes mammalian host cells and culture media. Enhancers and small bioreactors are included with related service workflows. Early bio-production studies use these systems for fast protein supply. Scope excludes bacterial expression and yeast expression.

Mammalian Transient Protein Expression Market Inclusions

Scope includes HEK293 systems and CHO systems. It also includes expression vectors and transfection reagents. Suspension cells and culture media are included with process enhancers. Small bioreactors and contract expression services are included across global demand.

Mammalian Transient Protein Expression Market Exclusions

Scope excludes bacterial expression and yeast expression. It excludes insect expression and stable clone selection. Commercial fill-finish work and large-scale GMP manufacturing are outside scope. Protein purification-only services and diagnostic kit production are excluded.

Mammalian Transient Protein Expression Market Research Methodology

• Primary Research: FMI analysts reviewed input from biopharma research teams and CRO service managers. Reagent suppliers and cell culture specialists informed the second review layer. Platform users added feedback on practical workflow issues. The review focused on yield reliability and turnaround time. Cell viability and protocol transfer support shaped the final buying criteria.
• Desk Research: Desk work used official company product information and scientific literature. Regulatory references and public funding sources supported the scope review. Product scope was defined around mammalian systems used for transient expression of proteins and antibodies.
• Market Sizing and Forecasting: The model combined reagent use frequency and project count. It reviewed service pricing and platform penetration. Country-level research intensity supported the final forecast.
• Data Validation: Forecasts were validated through comparison with antibody research activity and recombinant DNA use. Protein purification demand supported the final cross-check. Company portfolios were reviewed to confirm active participation in vectors and expression services.

Why is the Mammalian Transient Protein Expression Market Expanding?

• Antibody screening programs need faster protein batches before teams commit resources to stable cell-line work.
• Recombinant protein studies use mammalian hosts as folding and glycosylation can determine assay value.
• CRO service demand is increasing as small biotech firms outsource expression work before funding milestones.
• HEK293 workflows support fast turnaround as many discovery teams need rapid samples for functional assays.
• CHO workflows support comparability with later manufacturing hosts and reduce technical change during scale work.

Antibody discovery creates repeat demand for transient expression systems as each candidate panel needs fresh protein material. FDA’s Center for Drug Evaluation and Research approved 50 new drugs in 2024, with biologics and targeted therapies keeping early protein work active. This approval process puts pressure on discovery teams to generate decision-ready protein material before clinical candidates reach filing stage. Expression vendors benefit as research teams screen more antibody forms and need quick protein lots for binding tests.

Recombinant protein work favors mammalian systems when protein folding affects assay reliability and therapeutic relevance. Scientific literature from 2024 and 2025 continues to identify CHO and HEK293 systems as core hosts for transient gene expression in antibodies and complex proteins. This reinforces use in early testing as bacterial systems often miss mammalian post-translational patterns. Suppliers with vector design and transfection chemistry reduce troubleshooting time. Media optimization improves output stability during difficult expression programs. The result is higher repeat use among labs developing complex antibodies and glycoproteins.

Market Segmentation Analysis

• Expression vectors are projected to account for 28.5% share in 2026 as construct quality shapes yield and assay output.
• Bio-production is expected to account for 40.0% share in 2026 with antibody and antigen batches driving demand.
• HEK293 is projected to represent 46.0% share in 2026 as fast expression supports discovery timelines.
• Biopharma Companies are expected to hold 48.0% share in 2026 with internal discovery teams using repeated runs.
• Small Scale is projected to represent 42.0% share in 2026 as most projects need limited protein quantities.

The market is segmented by product category into expression vectors, reagents, competent cells, and instruments, each supporting different stages of transient protein production. It is further segmented by application across bio‑production, drug discovery, functional assays, and vaccine research, reflecting broad use in early biologics workflows. Segmentation by expression host includes HEK293, CHO, hybridoma, and other mammalian systems, with HEK293 leading due to rapid transfection performance. By end user and scale, the market spans biopharma companies, CROs, academic institutes, and research labs, operating from micro‑scale to high‑throughput production.

Mammalian Transient Protein Expression Market Analysis By Product Category

• Expression vectors are projected to account for 28.5% of product category in 2026 as plasmid architecture affects expression yield and protein recovery during early assay work.
• Buyers often choose premium vectors for difficult proteins. Weak signal or poor secretion can waste weeks of screening time across antibody programs.

Mammalian Transient Protein Expression Market Analysis By Application

• In 2026, bio-production is expected to represent 40.0% of application segment with antibody and antigen sample needs supporting repeated transient expression cycles.
• Drug discovery teams often use bio-production batches before stable clone investment. Early purity and activity data decide which molecules advance.

Mammalian Transient Protein Expression Market Analysis By Expression Host

• HEK293 is anticipated to represent 46.0% of expression host in 2026 as fast transfection and high protein output suit screening projects.
• CHO is preferred in later comparability work since many commercial biologics use CHO manufacturing paths and need closer process alignment.

Mammalian Transient Protein Expression Market Analysis By End User

• Biopharma Companies are projected to account for 48.0% market share in 2026 with internal antibody and protein engineering teams using repeat workflows.
• CROs win overflow work from smaller biotech firms as service contracts reduce the need for in-house cell culture teams.

Mammalian Transient Protein Expression Market Analysis By Scale

• Small Scale is expected to represent 42.0% share in 2026 as most discovery programs need milligram to gram output.
• High throughput formats support screening campaigns with many constructs and limited protein volume per candidate.

Mammalian Transient Protein Expression Market Drivers, Restraints, and Opportunities

• Antibody complexity drives demand for mammalian hosts since protein folding can change binding and assay results.
• Screening volume supports repeat reagent use as each new construct needs vectors and transfection chemistry.
• High reagent cost limits broad use in academic labs with tight project budgets and frequent failed runs.
• CRO outsourcing creates opportunity as small biotech firms need fast protein samples without expanding internal capacity.
• CHO transient systems create opportunity as projects seek closer alignment with later production hosts.

Antibody Screening Workloads

Antibody screening is the most direct demand path for mammalian transient expression systems. Buyers need fast protein lots for binding assays and functional testing. Developability review happens before stable cell-line spending begins. Research antibodies demand supports this workflow as validated binding tools shape laboratory decisions. Expression suppliers gain advantage when systems reduce failed runs and support difficult molecules. This creates a practical buying test around turnaround time and yield range. Protein activity after purification shapes final supplier choice.

Biological Output Prices Are Supporting Selective Pass-Through

Price movement in the Mammalian Transient Protein Expression Market is directly linked to the selling-price environment for biologics and pharmaceutical preparation outputs, because transient expression services are commonly priced around cell-line platform use and delivery timelines. In BLS’ Producer Price Indexes, updated in March 2026, biological products including diagnostics increased 3.2% from March 2025 to March 2026. Pharmaceutical preparations increased 0.8% over the same period. This does not create blanket pricing power. CDMOs and expression-service providers can defend pass-through for higher-grade plasmids and analytical QA where clients require regulated-development readiness.

Consumables Costs Are Creating Quote Volatility

Transient mammalian expression pricing is exposed to upstream consumables rather than only final biologics pricing. BLS’ March 2026 PPI table shows industrial gases up 12.6% from March 2025 to March 2026 - unsupported plastic film and other shapes up 4.8%. Industrial chemicals down 0.5% and plastic resins and materials down 3.5%. For expression-service buyers, the mixed signal is important: some inputs used around bioreactor operations and single-use systems remain inflationary. Selected chemical and resin categories are softer. Suppliers should avoid long fixed-price quotes unless volumes and expedited timelines are tightly defined.

Analysis of Mammalian Transient Protein Expression By Key Countries

Country	CAGR
South Korea	6.4%
China	6.2%
India	6.0%
USA	5.8%
Germany	5.6%
Japan	5.2%
UK	5.0%

Source: FMI analysis based on primary research and proprietary forecasting model.

Mammalian Transient Protein Expression CAGR Analysis By Country

• South Korea is projected to record a 6.4% CAGR through 2036 as biologics investment supports advanced expression workflows.
• China is expected to expand at 6.2% CAGR through 2036 with domestic antibody discovery and CRO activity supporting demand.
• India is forecast to grow at 6.0% CAGR through 2036 as biosimilar research and contract services increase expression use.
• The USA is expected to advance at 5.8% CAGR through 2036 as biotech clusters support repeat research purchases.
• Germany is projected to rise at 5.6% CAGR through 2036 with process science and biologics research supporting steady demand.
• Japan is forecast at 5.2% CAGR through 2036 as domestic biologics programs sustain platform use.
• The UK is expected to post 5.0% CAGR through 2036 as life science hubs support early protein research.

Demand Outlook for Mammalian Transient Protein Expression in South Korea

South Korea has a established biologics production base and a fast-expanding research services base across Incheon and Seoul. The country is expected to post 6.4% CAGR through 2036 as domestic biologics firms focus on early research and scale-up capability. Public support for bioeconomy programs strengthens supplier confidence in advanced cell culture tools.

• Incheon’s Songdo cluster supports biologics activity through large-scale manufacturing and supplier access for cell culture systems.
• South Korea’s Ministry of Health and Welfare supports biohealth policy programs with emphasis on drugs and medical technology.
• Seoul research hospitals and biotech firms create repeat demand for bioprocess technology used in early protein work.

Sales Analysis of Mammalian Transient Protein Expression in China

China’s demand is shaped by domestic antibody pipelines and CRO capacity serving local and overseas clients. The country is projected to expand at 6.2% CAGR through 2036 with Shanghai and Suzhou supporting high research density. Local service providers compete through speed and bundled gene-to-protein workflows. Imported premium systems serve complex projects needing reproducibility across sites. Any increase in domestic reagent quality would shift more spending toward local suppliers and improve price access.

• Shanghai Zhangjiang remains a major life science base with antibody discovery firms and service providers.
• Suzhou BioBAY supports biotech firms needing expression services and early protein testing capacity.
• China’s biologics firms use recombinant DNA tools across discovery and process development work.

Demand Analysis of Mammalian Transient Protein Expression in India

India’s market is supported by biosimilar research and contract service expansion across Hyderabad and Bengaluru. The country is forecast to grow at 6.0% rate through 2036 as research teams expand antibody and recombinant protein workflows. Buyers often compare imported kits with lower-cost service options from local providers. Budget pressure remains a constraint in academic labs. Stronger CRO documentation and faster delivery could increase outsourced expression volumes across domestic biotech programs.

• Hyderabad’s Genome Valley supports biologics research and contract service activity across Telangana.
• Bengaluru life science firms use expression workflows for antibody discovery and recombinant protein studies.
• India’s BioE3 policy focus supports bio-manufacturing and related research capacity across national programs.

Opportunity Analysis of Mammalian Transient Protein Expression in the USA

The USA has the deepest buyer base due to biotech clusters and academic labs. Large pharmaceutical research centers further increases demand. The country is expected to advance at 5.8% CAGR through 2036 as discovery programs keep using transient expression before stable-line work. Demand is concentrated around Boston and San Diego. The San Francisco Bay Area is another major research base. Suppliers win through local support and validated protocols across HEK293 and CHO systems. Faster sample-to-assay cycles could lift premium platform use in early biologics work.

• Boston-Cambridge supports repeated antibody and protein engineering work across universities and biotech firms.
• San Diego firms rely on CRO access and local supplier networks for fast research material.
• NIH-funded biomedical research supports demand for protein expression tools across academic labs.

Future Outlook for Mammalian Transient Protein Expression in Germany

Germany’s demand reflects process science strength and established biologics research across Munich. Heidelberg and North Rhine-Westphalia enhance research depth. Germany is projected to rise at 5.6% CAGR through 2036 with pharma and research institutes using expression systems for protein characterization. Higher CHO workflow use would support premium cell line and media demand across process-linked research.

• Munich’s biotech cluster supports antibody research and translational protein work across academic and private labs.
• Heidelberg research institutions support structural biology and recombinant protein demand.
• North Rhine-Westphalia gives suppliers access to pharma users and protein purification workflows.

Demand Outlook for Mammalian Transient Protein Expression in Japan

Japan’s demand is shaped by steady biologics research and careful platform qualification across Tokyo and Osaka. Japan is forecast at 5.2% CAGR through 2036 as domestic pharma companies keep using transient expression for early screening. Buyers often prefer systems with documented reproducibility and documented technical support. Adoption can move slowly due to validation routines inside established research teams. Better integration between expression and purification would support higher spend per project.

• Tokyo research hubs support antibody and recombinant protein work across pharma and university labs.
• Osaka’s pharmaceutical base creates demand for validated mammalian expression workflows.
• AMED funding programs support medical research connected with biologics and advanced therapy development.

In-depth Analysis of Mammalian Transient Protein Expression in the UK

The UK demand base is shaped by academic science and biotech clusters. Contract research activity around Cambridge and Oxford increases demand. The UK is expected to post 5.0% CAGR through 2036 as translational programs need assay-grade proteins. Buyers face funding cycles that can delay large kit purchases. CROs gain share by offering packaged gene-to-protein services. Stable public funding and private biotech investment would support broader use of antibody therapy research workflows.

• Cambridge supports antibody discovery and protein engineering through university spinouts and biotech firms.
• Oxford research groups create demand for recombinant proteins used in structural biology and immunology.
• UKRI funding supports bioscience research and reinforces demand for advanced lab workflows.

Competitive Landscape and Strategic Positioning

• Market concentration is moderate as large suppliers control platform depth and smaller firms compete through service speed.
• Established companies lead through expression kits and technical support for failed runs.
• Specialist CROs compete through bundled gene-to-protein services and faster antibody delivery timelines.
• Entry barriers include cell culture know-how and validated protocols. Reagent reliability and customer trust shape repeat projects.

Competition is built around platform reliability during early biologics work. Thermo Fisher Scientific holds a clear position with Expi293 and ExpiCHO systems across transient protein production. The company introduced Gibco Expi293 PRO in August 2025 as a next-generation HEK293 transient expression system for difficult proteins. This development holds importance as buyers want higher yield without rebuilding protocols. Suppliers with broad cell separation and protein workflows gain account access across research teams.

Capability depth separates established firms from smaller suppliers. Sartorius expanded production of GMP transfection reagents in Illkirch, France in September 2025. The move strengthens supply for cell and gene therapy workflows and supports reagent confidence in adjacent expression work. Cytiva introduced transient cell lines for AAV work in April 2024, which reinforces its position across viral vector and mammalian cell workflows. Buyers favor vendors able to support transfection and culture. Purification support reduces extra vendor handoffs.

Specialist service providers win through turnaround time and custom support. GenScript and Bioelectronica announced a strategic collaboration in August 2025 to link HyperCell screening with GenScript’s TurboCHO transient expression workflow. The TurboCHO platform supports purified antibodies in as little as five business days. Sino Biological competes through recombinant protein and antibody supply across research clients. Lonza supports customers through mammalian expression and process development strength. Entry remains hard as customers avoid switching after a platform produces reliable assays.

Companies in the Mammalian Transient Protein Expression Market

Competitive structure favors suppliers with expression systems, cell culture depth, and documented support across antibody programs.

• Global Leaders: Thermo Fisher Scientific and Merck KGaA compete through broad portfolios covering vectors and media. Cytiva and Sartorius compete through reagents and host-cell support. Lonza adds bioprocess support across research and development work.
• Specialist Service Providers: GenScript and Sino Biological compete through protein expression services and recombinant protein supply. Their position is clearest among biotech firms and academic labs needing purified proteins without building internal cell culture capacity.
• Regional and Emerging Players: Smaller CROs and reagent suppliers compete through local access and lower project cost. Custom antibody workflows help them win early-stage projects. These firms often win early-stage orders from academic groups and small biotech teams.

Competitive Benchmarking: Mammalian Transient Protein Expression Market

Company	Vector-System Depth	Mammalian Host Coverage	Protein Delivery Support	Geographic Footprint
Thermo Fisher Scientific	High	High	Strong	Global
Merck KGaA	High	Strong	Strong	Global
Cytiva	Strong	High	Strong	Global
Sartorius	Strong	High	Strong	Global
Lonza	Strong	High	Strong	Global
GenScript	Medium	Strong	High	Global
Sino Biological	Medium	Medium	High	Global
Takara Bio	Medium	Medium	Moderate	Asia and North America

Source: Future Market Insights competitive analysis 2026. Ratings reflect relative positioning based on vector-system depth and mammalian host coverage.

Developments in Mammalian Transient Protein Expression Market

• In August 2025, Thermo Fisher Scientific introduced Gibco Expi293 PRO Expression System for next-generation HEK293 transient expression. The system supports difficult protein research and higher throughput workflows.
• In September 2025, Sartorius expanded production of GMP transfection reagents in Illkirch, France. The expansion strengthens supply for cell and gene therapy workflows connected with transient transfection demand.
• In April 2024, Cytiva introduced transient cell lines supporting AAV workflow flexibility. The launch strengthens Cytiva’s position across cell culture and expression-adjacent research systems.
• In August 2025, GenScript and Bioelectronica announced a strategic collaboration linking antibody screening with TurboCHO transient expression. The collaboration supports faster validation after single-cell screening.
• In March 2026, Sartorius launched a rational-design CHO host cell line with higher productivity. The launch reinforces supplier focus on CHO performance and scale confidence.

Players in the Mammalian Transient Protein Expression Market

Global Leaders

• Thermo Fisher Scientific
• Merck KGaA
• Cytiva
• Sartorius
• Lonza

Specialist Service Providers

• GenScript
• Sino Biological

Regional and Emerging Players

• Takara Bio
• Creative Biolabs
• Leinco Technologies

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 848.5 million in 2026 to USD 1,449.4 million by 2036 at 5.5% CAGR
Market Definition	Systems used to produce recombinant proteins in mammalian cells without stable genome integration
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, China, India, Germany, Japan, UK, South Korea, and 30+ countries
Key Companies Profiled	Thermo Fisher Scientific, Merck KGaA, Cytiva, Sartorius, Lonza, GenScript, Sino Biological
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using verified demand signals, project frequency, pricing, and platform use rates

Mammalian Transient Protein Expression Breakdown By Product Category, Application, Host, End User, Scale, and Region

Mammalian Transient Protein Expression Market Segmented by Product Category:

• Expression Vectors
• Reagents
• Competent Cells
• Instruments

Mammalian Transient Protein Expression Market Segmented by Application:

• Bio-production
• Drug Discovery
• Functional Assays
• Vaccine Research

Mammalian Transient Protein Expression Market Segmented by Expression Host:

• HEK293
• CHO
• Hybridoma
• Others

Mammalian Transient Protein Expression Market Segmented by End User:

• Biopharma Companies
• CROs
• Academic Institutes
• Research Labs

Mammalian Transient Protein Expression Market Segmented by Scale

• Micro Scale
• Small Scale
• Pilot Scale
• High Throughput

Mammalian Transient Protein Expression Market by Region:

• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan and Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East and Africa

Research Sources and Bibliography

1. United States Bureau of Labor Statistics. (2026, April 14). Producer Price Indexes - March 2026.
2. Thermo Fisher Scientific. (2025). Expi293 PRO protein expression services. Thermo Fisher Scientific.
3. Sartorius. (2025, September 18). Sartorius expands production of key components for cell and gene therapies in France. Sartorius.
4. Sartorius. (2026, March 3). Sartorius launches rational-design CHO host cell line with up to three-fold increase in productivity. Sartorius.
5. Cytiva. (2024, April 30). Cytiva introduces new cell lines to meet the challenges of AAV production. Cytiva.
6. GenScript. (2025, August 30). GenScript and Bioelectronica announce strategic collaboration to accelerate antibody discovery. GenScript.
7. Fu, Y., et al. (2024). Improvement strategies for transient gene expression in mammalian cells. National Library of Medicine.
8. Chavalparit, T., et al. (2025). Rapid expression of therapeutic antibodies in mammalian cells. National Library of Medicine.
9. Hederoth, G., et al. (2025). Updated transient gene expression protocol in Expi293F cells. National Library of Medicine.

This bibliography is provided for reader reference and includes market pages, official company sources, and scientific publications used for article development.

This Report Answers

• What is the expected market size for mammalian transient protein expression systems in 2026 and 2036?
• What CAGR is projected for mammalian transient protein expression demand during the 2026 to 2036 period?
• Which product category is projected to lead demand in mammalian transient protein expression workflows?
• Which application area is expected to account for the largest share of transient expression spending?
• What demand factors support wider use of HEK293 and CHO transient expression systems?
• Which countries are expected to record faster expansion in mammalian transient protein expression demand?
• Which companies compete through vectors, reagents, host cells, expression systems, and protein services?
• What products and workflows are included in mammalian transient protein expression scope?
• What methodology supports the forecast for mammalian transient protein expression demand?